• In early June 2026, Eli Lilly reported Phase 3 data showing its oral GLP-1 Foundayo delivered significant weight loss across menopausal stages, while its investigational triple-agonist retatrutide produced substantial weight loss and improvements in obesity-related conditions such as knee osteoarthritis pain, obstructive sleep apnea, and type 2 diabetes.
• Together with broadened insurance coverage for Zepbound and Foundayo and new LillyDirect partnerships, these results point to Eli Lilly building an integrated obesity care ecosystem spanning powerful therapies, improved access, and wraparound digital and behavioral support.
• We’ll now examine how Foundayo’s strong menopause data and expanded PBM coverage may influence Eli Lilly’s investment narrative in obesity care.

AI is about to change healthcare. These 38 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

Eli Lilly Investment Narrative Recap

To own Eli Lilly today, you need to believe its GLP‑1 and incretin platform can support premium economics even as payers and regulators push on price and access. The latest Foundayo menopause data and retatrutide Phase 3 results reinforce the obesity thesis, while broad PBM coverage directly supports the key near term catalyst of sustained GLP‑1 volume growth. The biggest risk remains payer and policy pushback on obesity drug costs and coverage breadth.

The May 28 announcement that all three of the largest U.S. PBMs will cover Lilly’s full obesity portfolio, including Foundayo and Zepbound, feels especially relevant here. It reduces formulary exclusion risk at the same time Foundayo’s menopause data and retatrutide’s Phase 3 results expand the clinical story, tightening the link between access, real world uptake, and how much of Lilly’s current premium valuation is tied to GLP‑1 execution.

Yet beneath the strong obesity headlines, investors should still be watching how concentrated Lilly’s earnings remain in a handful of incretin products as...

Eli Lilly's narrative projects $113.6 billion revenue and $46.8 billion earnings by 2029.

Uncover how Eli Lilly's forecasts yield a $1211 fair value, a 7% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were already assuming revenues could reach about US$124.5 billion by 2029, and see Foundayo’s oral profile and LillyDirect as proof that small molecule scale and direct channels could blunt payer power, whereas the baseline view still treats PBM leverage and pricing pressure as a central risk that these new data and access wins might or might not soften.

Explore 19 other fair value estimates on Eli Lilly - why the stock might be worth as much as 33% more than the current price!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Eli Lilly research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Eli Lilly research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Eli Lilly's overall financial health at a glance.

Ready For A Different Approach?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• Outshine the giants: these 13 early-stage AI stocks could fund your retirement.
• Rare earth metals are the new gold rush. Find out which 27 stocks are leading the charge.
• Uncover the next big thing with 24 elite penny stocks that balance risk and reward.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.